ArticleScientific reports2025
An in- vitro measurement for the toxicity of peptides inhibit hexokinase II in breast cancer cell lines.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibiotic-chemotherapy interaction in brain tumors: cefazolin reduces chemotherapeutic efficacy of irinotecan in glioblastoma and neuroblastoma cells.Medical oncology (Northwood, London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of the enzyme hexokinase 2 in many cancers has been identified through increased glycolysis or binding to the pro-apoptotic channel located in the outer mitochondrial membrane, (VDCA1) and protein kinase (MTOR). To prevent the cancer-causing pathways of this enzyme, it is possible to disrupt the interaction of hexokinase subunits. Peptides can be utilized to interfere with the interaction of subunits by binding to amino acids that contribute to enzyme dimerization. Nowadays, peptides have become a suitable option for the treatment of various diseases, especially cancer, due to their small size, ease of synthesis, and ability to penetrate the tumor. This study examined the toxic effect of peptides that inhibit enzyme interaction on tumorigenic MCF-7 and MDA-MB-231 and non-tumorigenic MCF10A cell lines through MTT analysis and flow cytometry to determine cell apoptosis. The MCF-7 line experienced a significant decrease in cell proliferation with both peptides. The RYALFSS peptide caused a decrease in the number of MDA-MB-231 cells, but the EKGLGATTHPTAAVKML peptide caused a significant increase. There was no significant increase or decrease in the MCF10A cell line. The study's finding indicate that peptides can serve as a tool to prevent the proliferation of carcinogenic cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.